CTRI/2018/08/015338
Completed
未知
A Non-interventional, multicentre study to assess prevalence of BRCA1 and BRCA2 mutation among ovarian, primary peritoneal and fallopian tube cancer patients in India ( BRCA Study) - BRCA Study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- AstraZeneca Pharma India Ltd
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients who provide written informed consent
- •2\. Female ââ?°Â¥ 18 years of age
- •3\. Previously or newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer patients.
Exclusion Criteria
- •1\. Patient with any medical condition that, in the opinion of the investigator, would interfere with safe completion of the study
- •2\. Patient participating in any other clinical study/ trial.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study to determine the local prevalence in Indian patients in Prostate cancerCTRI/2021/12/038578AstraZeneca Pharma India Ltd211
Active, not recruiting
Not Applicable
A study investigating the effectiveness, safety and quality of life in participants with age related visual impairment (macular degeneration) who have switched to faricimab, under real world conditions in Germanyeovascular age related macular degeneration (nAMD)Eye DiseasesISRCTN27514808Roche Pharma (Roche Germany)620
Recruiting
Not Applicable
Benefits of Standard ONS in Indian AdultsCTRI/2019/05/018917Abbott Healthcare Pvt Ltd
Completed
Not Applicable
Multicentre Non-interventional Study of Treatment Outcome in Heart Failure Patients with Hyperkalaemia under RAASi-treatment Receiving Veltassa in Routine PracticeE87.5HyperkalaemiaDRKS00014825Vifor Pharma Deutschland GmbH22
Completed
Not Applicable
A Prospective, Multi-centre Study to Evaluate the Clinical Performance of the GYNECARE PROLIFT +M* Pelvic Floor Repair System as a Device for Pelvic Organ ProlapseProlapse1004682810029903NL-OMON31625Ethicon_Johnson & Johnson Medical Ltd20